Abstract

A method for producing a modified wooden material. Specifically described is a method for producing a modified wooden material, the method including: 1) a step for causing permeation, into a wooden material, of a 5-hydroxymethylfurfural (5-HMF) resinification solution containing 5-HMF and an inorganic salt for promoting polymerization of the 5-HMF; and 2) a step for polymerizing the 5-HMF of the permeated 5-HMF resinification solution in the wooden material by means of heating.

IPC Classes  ?

• B27K 3/34 - Organic impregnating agents
• B27K 3/15 - Impregnating involving polymerisation
• C08G 16/02 - Condensation polymers of aldehydes or ketones with monomers not provided for in the groups of aldehydes

Abstract

The present disclosure provides a method for producing growth factor-producing cells by inducing differentiation directly from somatic cells, and a composition for producing growth factor-producing cells by inducing differentiation directly from somatic cells.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention addresses the problem of providing: a novel treatment strategy using a molecular targeted drug in cancer patients having a driver mutation; a novel method capable of identifying a treatment target patient group suitable for the novel treatment strategy, and capable of predicting, monitoring, or diagnosing a response to the novel treatment strategy; and a kit for use in the method. The present invention provides, as a means for solving the problem, a pharmaceutical composition which contains, as an active ingredient, a FAK inhibitor and a RAF/MEK dual inhibitor for use in the treatment of, for example, patients suffering from cancer, and which is for administration to patients who have been confirmed that an epithelial biomarker expression level in a tumor sample isolated from a patient is higher than the mesenchymal biomarker expression level.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention discloses a method for producing a modified wooden material. Specifically disclosed is a method for producing a modified wooden material, said method comprising: 1) a step for causing permeation, into a wooden material, of a 5-hydroxymethylfurfural (5-HMF) resinification solution containing 5-HMF and an inorganic salt for promoting polymerization of the 5-HMF; and 2) a step for polymerizing the 5-HMF of the permeated 5-HMF resinification solution in the wooden material by means of heating.

IPC Classes  ?

• B27K 3/15 - Impregnating involving polymerisation
• B27K 3/38 - Aromatic compounds
• B27K 3/50 - Mixtures of different organic impregnating agents
• B27K 3/52 - Impregnating agents containing mixtures of inorganic and organic compounds

Abstract

The present invention provides a composition for transdermal administration comprising a nucleic acid. Specifically, the present invention provides a composition for transdermal administration comprising a nucleic acid, the nucleic acid comprising RNA, wherein the composition is administered by an administration method comprising spraying the composition to the surface of a target tissue, and the spraying of the composition is performed by pressurization of the composition, whereby the composition is sprayed toward the target tissue and penetrates the surface of the target tissue.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides an engineered protein that can be utilized as a genome engineering tool. The protein comprises the amino acid sequence represented by SEQ ID NO: 1 in which amino acid at position 188 is substituted with histidine, the amino acid sequence further including one selected from: substitution of amino acid at position 2 with tyrosine; substitution of amino acid at position 70 with tyrosine; substitution of amino acid at position 80 with arginine; substitution of amino acid at position 105 with threonine; substitution of amino acid at position 123 with histidine; substitution of amino acid at position 195 with lysine; substitution of amino acid at position 208 with arginine; substitution of amino acid at position 232 with alanine; substitution of amino acid at position 246 with methionine; substitution of amino acid at position 316 with methionine; and substitution of amino acid at position 337 with isoleucine.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/55 - Hydrolases (3)

Abstract

The present invention addresses the problem of providing a method for producing a suprachiasmatic nucleus cell organoid. The problem is solved by a method for producing a suprachiasmatic nucleus organoid comprising: (1) a step for culturing pluripotent stem cells in an intermediate medium between an undifferentiation maintenance medium and a nerve differentiation medium; (2) a step for culturing the cells obtained in step (1) in a nerve differentiation medium; and (3) a step for performing an operation for forming a cell mass prior to the start of step (2), wherein (A) the number of raw material cells seeded in order to form one cell mass is 6000 or more, and (B) when the start of step (2) is taken as day 0, the medium contains a sonic hedgehog signaling pathway agonist from day 3 onward.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• C12N 5/079 - Neural cells

Abstract

Provided is a urination dynamics identification device capable of identifying urination dynamics, and an imaging device. In order to identify the dynamics of urination released from a human body over time, the device comprises: an identification section (urination-related value calculation section 4) that, on the basis of an image of a surface that is caused to intersect by irradiating the released urination with planar light, identifies a split state of urination on said surface as the dynamics of urination over time; and an output section (calculation result output display section 46) that outputs information relating to the split state of the urination identified by the identification unit.

IPC Classes  ?

• A61B 5/20 - Measuring urological functions

Abstract

The present disclosure relates to a new screening method to search for compounds that have browning-promoting or browning-inhibiting effects on brown adipocytes and that target cell membrane receptors.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

An object of the present invention is to provide an improved β-fructofuranosidase and a method for manufacturing the same. According to the present invention, there are provided an improved β-fructofuranosidase consisting of an amino acid sequence of a β-fructofuranosidase in which either or both of an amino acid corresponding to the 81st position from an amino terminal of an amino acid sequence shown in SEQ ID NO: 1 and an amino acid corresponding to the 141st position from the amino terminal of the amino acid sequence shown in SEQ ID NO: 1 is/are substituted with another amino acid/other amino acids, and a method for manufacturing the same. The improved β-fructofuranosidase of the present invention is advantageous in that it can produce trisaccharide FOS while suppressing the production of tetra- or higher-saccharide FOS, and thus can produce a FOS having improved crystallinity and hygroscopicity, and is also advantageous in that it can provide prebiotics having higher functionality.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase

Abstract

The area selection assistance method includes: a step (step S11) for dividing a stained specimen image obtained by an immunostaining method into a plurality of divided areas; a step (step S12) for assigning, to the respective divided areas, one display color from a display color group including a plurality of colors having different levels of attractiveness such that the attractiveness becomes higher as the aggregation of the stained cells in the divided area becomes higher; a step (step S13) for generating a selection assistance image in which each of the plurality of divided areas is painted in the display color assigned in the step S12; and a step (step S14) for displaying the selection assistance image on a screen. Thus, the operator can easily select, as an analysis area, an area suitable for analysis in the stained image.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The disclosure provides gene transfer constructs comprising a destabilizing domain (DD) sequence, a translational separator sequence, and a sequence encoding one or more copies of one or more peptides of interest; nucleic acids encoding gene transfer constructs; uses of nucleic acids encoding gene transfer constructs to prevent mitochondrial hyperfission and fragmentation; uses of nucleic acids encoding gene transfer constructs to induce apoptosis in cells, such as cancer cells; and therapeutic applications of nucleic acids encoding gene transfer constructs, for example, in the treatment of mitochondrial diseases and disorders associated with mitochondrial dysfunction, as well as various types of cancer.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Methods of treating diseases and disorders treatable by AMPK activation with sephin1 and related compounds, for example metabolic syndrome, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, sarcopenia, a neuromuscular disorder, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular diseases, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, an eye disease or disorder, ocular neovascularization, β-hemoglobinopathy, cancer, fibrosis, cancer cachexia, and mitochondrial disease.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides a method for producing a chimeric antigen receptor T (CAR-T) cell, including a step of bead separating with a specific factor a T cell from a T cell source, wherein the specific factor is CD45RA+ or the like. The method enables production of CAR-T cells high antitumor property, and can produce highly functional CAR-T cells conveniently in a short time at a low cost.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

One problem to be solved by the present invention is to provide a composition for maintaining or improving life expectancy. The problem is solved by a composition for maintaining or improving life expectancy, which contains α-amino-n-butyric acid or a salt thereof that is pharmaceutically acceptable or is acceptable for a food.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A23L 33/175 - Amino acids
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The objective of the present invention is to provide a novel fructosylated maltitol and a method for producing the same. According to the present invention, provided is a method for producing a fructosylated maltitol, the method comprising a step (contacting step) for bringing β-fructofuranosidase into contact with sucrose and maltitol, wherein the β-fructofuranosidase has at least 60% sequence identity to the amino acid sequence represented by in SEQ ID NO: 1, and has a β-fructofuranosidase activity. According to the present invention, it is advantageous in that fructosylated maltitol can be produced simply and efficiently.

IPC Classes  ?

• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• C13K 13/00 - Sugars not otherwise provided for in this class

Abstract

Classifying dry eye syndrome using a measurement comprising a light-projecting unit projecting a predetermined pattern onto a cornea surface, an image capturing unit that repeatedly captures a reflected images of the pattern reflected off the cornea surface, an acquiring unit that acquires blurriness information according to a value indicating a blurriness level at a maximum portion of luminance values in a reflected image, for each of the captured multiple reflected images, and a classifying unit that acquires a classification result of a dry eye syndrome by applying multiple pieces of time-series blurriness information acquired by the acquiring unit to a learning model trained using multiple pairs of training input information. Providing a classification result of a dry eye syndrome corresponding to the training input information, and an output unit that outputs the classification result acquired by the classifying unit.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/14 - Arrangements specially adapted for eye photography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

Provided is an mRNA vaccine that includes mRNA encoding an antigen, at least one RNA oligomer hybridized to the mRNA, and a cationic polymer encapsulating the mRNA. The RNA oligomer includes (a) an RNA sequence comprising a sequence of 12-40 bases that are complementary to the mRNA sequence or (b) an RNA sequence that has at least 90% identity with a sequence of 12-40 bases that are complementary to the mRNA sequence and hybridizes to the mRNA. The RNA oligomer includes a polyethylene glycol modification. Through said configuration, the present invention provides a novel mRNA vaccine.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 37/04 - Immunostimulants
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/12 - Genes encoding animal proteins

Abstract

A therapeutic agent for solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and to be administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination has strong antitumor effect and is therefore useful for treatment of solid cancers.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Polypeptides having a mitochondrial targeting sequence (MTS), an endonuclease sequence, and a destabilizing domain sequence; nucleic acids encoding same; uses of the polypeptides and nucleic acids to induce mitophagy, increase mitochondrial turnover, and/or induce double strand breaks in mitochondrial DNA in a cell; and therapeutic applications of the foregoing, for example in the treatment of mitochondrial diseases and disorders.

IPC Classes  ?

• C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
• C12N 9/22 - Ribonucleases

Abstract

A urinary incontinence treatment device includes: a sensor for detecting urination; stimulation pads configured to apply a stimulus to a wearer; and a mechanical member including a stimulus generation unit for generating a signal for causing the stimulation pads to apply the stimulus to the wearer and a control unit for controlling the stimulus generation unit to generate the signal in response to urination detection by the sensor. The stimulation pads include a first pair of stimulation pads and a second pair of stimulation pads. The stimulus generation unit supplies electrical signals having different frequencies. The first pair of stimulation pads and the second pair of stimulation pads are arranged such that an electrical signal applied from the first pair of stimulation pads and an electrical signal applied from the second pair of stimulation pads intersect each other in the wearer's body and a resulting interference wave reaches the bladder.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes

Abstract

The purpose of the present invention is to provide a novel TRPA1 agonist.　The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lenthionine. The composition can enhance appetite and food consumption and ameliorate decreased appetite.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 36/062 - Ascomycota
• A61K 36/07 - Basidiomycota, e.g. Cryptococcus
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stein cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

A diagnostic optical microscope according to the present embodiment includes at least one laser light source (11) configured to generate laser light for illuminating a sample (40) containing a light absorbing material, a lens configured to focus the laser light to be focused on the sample (40), scanning means for changing a focusing position of the laser light on the sample (40), and a light detector (31) configured to detect laser light transmitted through the sample (40) as signal light. A laser light intensity is changed to obtain a nonlinear region in which the laser light intensity and a signal light intensity have a nonlinear relation due to occurrence of saturation of absorption in the light absorbing material when the laser light intensity is maximized. An image is generated based on a nonlinear component of the signal light based on the saturation of absorption in the light absorbing material.

IPC Classes  ?

• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 33/483 - Physical analysis of biological material
• G02B 21/00 - Microscopes

Abstract

The present invention achieves an image translation device, for example, that can effectively utilize an existing diagnostic imaging model. An image translation device (1) comprises an image translation unit (22) that includes a first generator (221) and a second generator (222), the image translation unit (22) having learned the relationship between a color-related feature of a first image group obtained by capturing images of a tissue on which a first process including an embedding process and slicing has been performed, and a color-related feature of a second image group obtained by capturing images of the tissue on which a second process that does not include the embedding process and slicing has been performed. A first object image belonging to the first image group or a second object image belonging to the second image group is input to the image translation unit (22), which then outputs a first translation image generated from the first object image or a second translation image generated from the second object image.

IPC Classes  ?

• G06T 7/00 - Image analysis
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

The present invention aims to provide a brown adipocyte and a generation method thereof, a transplantation material containing a brown adipocyte, a prophylactic agent or therapeutic agent containing a brown adipocyte for various diseases and conditions, and use thereof. Provided is a method for generating a brown adipocyte, including converting a differentiated somatic cell of a mammal to a brown adipocyte by culturing the somatic cell in a medium in the presence of at least one kind of a compound selected from the group consisting of (1) a TGFβ/SMAD pathway inhibitor, (2) a casein kinase 1 inhibitor, (3) a cAMP inducer and (4) a MEK/ERK pathway inhibitor.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues

Abstract

Disclosed are a partial peptide of cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP), consisting of an amino acid sequence of the conserved region of CAP, the peptide having at least one effect selected from the following effects: a plant stem cell-inducing effect, a plant environmental stress tolerance-enhancing effect, a plant pest resistance-inducing effect, a germination-promoting effect, a plant transformation efficiency-enhancing effect, and a plant growth-promoting effect; and a plant stem cell inducer, an environmental stress enhancer, a plant pest resistance inducer, a germination promoter, a transformation efficiency enhancer, and a plant growth promoter, all of which comprise the peptide.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.

IPC Classes  ?

• A61B 17/58 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
• A61L 31/02 - Inorganic materials
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

The present invention addresses the problem of providing an EGFR CAR-T cell which is expected to be effective against a tumor in which an EGFR is expressed. The present invention provides: a polynucleotide encoding a chimeric antigen receptor (chimeric antigen receptor: CAR) protein comprising a target binding domain capable of binding to an epidermal growth factor receptor (EGFR), a transmembrane domain and an intracellular signaling domain, in which the target binding domain is a ligand of an EGFR; a vector carrying the polynucleotide; and a genetically modified cell into which the polypeptide or the vector has been introduced.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention addresses the problem of providing: an inhibitory agent for myocardial cell death; and a prophylactic or therapeutic agent for myocardial disorders or heart failure. The problem is solved by an inhibitory agent for myocardial cell death or a prophylactic or therapeutic agent for myocardial disorders or heart failure, the agent containing at least one component selected from the group consisting of a TAOK1 function inhibitor and a TAOK1 expression inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 39/00 - General protective or antinoxious agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/079 - Neural cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

This cell detection device that detects a cell image in captured image data of a slide specimen prepared from a liquid in which cells are dispersed. The cell detection device comprises: an image data acquisition unit that acquires a plurality of image data at different resolutions; a first detection unit that detects a cell image candidate region in first image data; an identification unit that identifies a region corresponding to the candidate region in second image data of higher resolution than the first image data; and a second detection unit that detects a cell image from the region in the second image data. This arrangement allows for accurate and efficient diagnosis of cells in a liquid discharged from the human body.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials

Abstract

The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

An object of the present invention is to provide a therapeutic strategy in the solid tumor area and a means useful therefor to further advance the clinical application of CAR therapy. There is prepared a gene-modified lymphocyte which expresses a chimeric antigen receptor having an EphrinB2 extracellular domain at the antigen recognition site.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/725 - T-cell receptors
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention mainly addresses the problem of providing a novel method for rapidly inducing growth factor-producing cells from somatic cells, that is, a novel production method that allows rapid production of growth factor-producing cells from somatic cells.　Examples of the present invention include: a method for producing growth factor-producing cells, which is characterized by comprising a step for culturing somatic cells in the presence of at least one agent selected from the group consisting of TGF-β inhibitors, p53 inhibitors, and cAMP inducers; growth factor-producing cells obtained by said production method; and a method for producing a growth factor or an anti-inflammatory factor, the method comprising a step for extracting/isolating the growth factor or anti-inflammatory factor from said growth factor-producing cells.　The growth factor-producing cells obtained in the present invention are useful in regenerative medicine, and the like.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61L 27/38 - Animal cells
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 25/00 - Drugs for disorders of the nervous system
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

A method of producing a wood-based material that is modified is provided. Specifically, there is provided a method of producing a wood-based material, comprising 1) a step of impregnating a wood-based material with a furan derivative resinification solution that comprises a furan derivative, an inorganic salt inhibiting polymerization of the furan derivative at normal temperature, and an inorganic salt accelerating polymerization of the furan derivative; and 2) a step of polymerizing the furan derivative in the furan derivative resinification solution impregnated into the wood-based material within the wood-based material by means of heating.

IPC Classes  ?

• B27K 3/15 - Impregnating involving polymerisation
• B27K 3/34 - Organic impregnating agents
• B27K 3/32 - Mixtures of different inorganic impregnating agents
• B27K 3/20 - Compounds of alkali metals or ammonium
• B27K 3/08 - Impregnating by pressure
• B27K 5/00 - Staining or dyeing woodBleaching woodTreating of wood not provided for in groups or

Abstract

To provide a cell trait assay technique for identifying cultured human corneal endothelium cells of which early clinical effect manifestation and a long-term stable clinical effect are confirmed, in clinical trials. Provided is a method of manufacturing a functional human corneal endothelial cell capable of eliciting a human corneal function when infused into an anterior chamber of a human eye, the method comprising the step of proliferating and/or differentiating or maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress, such as proliferation stress. Further, provided is a functional human corneal endothelial cell in which expression of a functional protein leading to a corneal endothelial (cell) functional property leading to improvement on corneal opacity and hydrous edema, resulting in continuous and long-term retention of corneal endothelial tissue cell density and improvement on visual acuity is recognized or in which a protein that inhibits the corneal endothelial (cell) functional property is not elicited or is reduced.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention provides a protein molecule effective for an anti-Pseudomonas aeruginosa vaccine. A protein molecule comprising PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.

IPC Classes  ?

• A61K 39/104 - Pseudomonas
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents

Abstract

A decision-making ability evaluation device 20 for use in evaluating the decision-making ability of a test subject regarding the use of a product or a service is provided with: a voice data acquisition unit 230 that acquires voice data of a test subject from an interaction related to the use of a product or a service; a conversion unit 231 that converts the voice data of the test subject acquired by the voice data acquisition unit 230 into text data; and a determination unit 233 that determines the decision-making ability of the test subject regarding the use of the product or the service on the basis of the text data obtained by the conversion performed by the conversion unit 231.

IPC Classes  ?

• G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
• G06F 40/216 - Parsing using statistical methods

Abstract

The present invention discloses a method for producing a modified wooden material. Specifically disclosed is a method for producing a modified wooden material, the method including: 1) a step for causing permeation, into a wooden material, of a furan derivative resinification solution containing a furan derivative, a polyalcohol, and an inorganic salt that promotes polymerization of the furan derivative; and 2) a step for polymerizing the furan derivative of the permeated furan derivative resinification solution in the wooden material by means of heating.

IPC Classes  ?

• B27K 3/15 - Impregnating involving polymerisation

Abstract

The present invention discloses a method for producing a modified wooden material. Specifically disclosed is a method for producing a modified wooden material, said method comprising: 1) a step for causing permeation, into a wooden material, of a 5-hydroxymethylfurfural (5-HMF) resinification solution containing 5-HMF and an inorganic salt for promoting polymerization of the 5-HMF; and 2) a step for polymerizing the 5-HMF of the permeated 5-HMF resinification solution in the wooden material by means of heating.

IPC Classes  ?

• B27K 3/15 - Impregnating involving polymerisation
• B27K 3/38 - Aromatic compounds
• B27K 3/50 - Mixtures of different organic impregnating agents
• B27K 3/52 - Impregnating agents containing mixtures of inorganic and organic compounds

Abstract

The present invention provides a composition for transdermal administration, which contains a nucleic acid. More specifically, the present invention provides a composition for transdermal administration, the composition containing a nucleic acid, in which the nucleic acid comprises RNA. The composition is administered by an administration method comprising spraying the composition onto the surface of a target tissue, in which the spraying of the composition is performed by applying a pressure to the composition so that the composition is sprayed toward the target tissue and penetrates through the surface of the target tissue.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61M 5/307 - Media expelled from injector by pressurised fluid
• A61P 37/02 - Immunomodulators
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention addresses the problem of producing an antibody-mimetic molecule that can be treated by an autoclave. The problem is solved by an antibody-mimetic molecule which has, as a backbone thereof, a cold shock protein (CSP) or cold shock domain (CSD) containing at least one mutated structure surface amino acid, and which is bound, at a strength Kd of at least 10000 nM or less, to a target molecule to which the CSP or the CSD before the introduction of the mutation cannot be bound at a strength Kd of at least 10000 nM or less.

IPC Classes  ?

• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof

Abstract

A method for diagnosing the risk of glaucoma development, which can diagnose the risk of glaucoma development at the pre-disease stage, and to provide a new method to diagnose disease progression in the end-stage glaucoma. The method can include, for example, a diagnosing method for the risk of an ocular disease development or for the disease progression of an end-stage ocular disease by molecular profile analysis of the ocular anterior tissue microenvironment, comprising a step of measuring the concentration level of a metabolite appearing in the collected aqueous humor specimens by mass spectrometry (MS).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

According to the present invention, provided is a composition for inducing satiety or suppressing overeating.　This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provides a GABA-containing composition for suppressing overeating in a subject when the subject is hungry.

IPC Classes  ?

• A23L 33/175 - Amino acids
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/06 - Antimigraine agents
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to newly discover a transient receptor potential ankyrin 1 (TRPA1) agonist that exhibits an action for increasing the amount of food ingested, to provide a novel agonist of TRPA1, or to provide a novel active ingredient that exhibits an action for increasing the amount of food ingested or an action for improving anorexia.　A compound having a specific fatty acid or a specific anthraquinone structure has an effect for activating TRPA1 and can be used as an active ingredient for increasing the amount of food ingested and/or improving anorexia.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/12 - Fatty acids or derivatives thereof
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 50/16 - Quinones the quinoid structure being part of a condensed ring system containing three rings
• C07C 66/02 - Anthraquinone carboxylic acids

Abstract

The present invention provides a method for producing chimeric antigen receptor T (CAR-T) cells, the method comprising a step for isolating, by means of beads, T cells from a T cell supply source using a specific factor. The specific factor is CD45RA+ or the like. The method enables production of CAR-T cells having high anti-tumor activity, and enables production of highly-functional CAR-T cells easily in a short period of time at a low cost.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A method for producing an organism including vascular endothelial cells, the method comprising incubating cells including human adipose-derived stem cells in the presence of a TGF-β type-I receptor inhibitor.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

[Problem] To provide a novel sarcopenic obesity inhibiting composition, and a prophylactic and/or therapeutic composition containing the same for improving sarcopenic obesity induced by diabetes. [Solution] A sarcopenic obesity inhibiting composition containing (A) guar gum degradation products having an average molecular weight of 1.7×103to 2.9×105, at least 70 mass% thereof being within this range, and (B) a guar bean protein, the viscosity of a 1 mass% aqueous solution of the composition being less than or equal to 50 mPa・s as measured at 25°C and 60 rpm using a B-type viscometer, wherein the guar gum degradation products are contained in guar-derived endosperm and obtained by using microbe-derived β-mannanase to hydrolyze and reduce the molecular weight of galactomannan polysaccharide that has a galactose to mannose content ratio (galactose:mannose) in the range 1:1.5 to 1:2.1, the dietary fiber content, defined by the enzymatic-HPLC method, is at least 70 mass%, the content of oligosaccharides in the guar gum degradation products 15 mass% or less, among the amino acid compositions in the contained proteins, (glutamic acid + glutamine + aspartic acid + asparagine) ≥ 100 mg/100g, (cystine + tyrosine + serine + threonine) ≥ 40mg/100g, and all amino acids ≥ 150mg/100g, and the ratio (A)/(B) is 1000 or less.

IPC Classes  ?

• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/17 - Amino acids, peptides or proteins
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The purpose of the present invention is to provide an improved β-fructofuranosidase and a method for producing same. The present invention provides an improved β-fructofuranosidase comprising an amino acid sequence provided by substituting, in the amino acid sequence of β-fructofuranosidase, another amino acid for either or both of the following: the amino acid corresponding to position 81 and the amino acid corresponding to position 141, in each case from the amino terminal of the amino acid sequence given by SEQ ID NO: 1. The present invention also provides a method for producing this improved β-fructofuranosidase. The improved β-fructofuranosidase according to the present invention can produce trisaccharide FOS while suppressing the production of tetrasaccharide and larger FOS, and is thus advantageous from the standpoint of enabling the production of FOS having an improved crystallinity and hygroscopicity, and is also advantageous from the standpoint of being able to provide prebiotics that exhibit a higher functionality.

IPC Classes  ?

• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/50 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin the cyclohexyl radical being substituted by two or more nitrogen atoms, e.g. destomycin, neamin having two saccharide radicals bound through only oxygen to adjacent ring carbon atoms of the cyclohexyl radical, e.g. ambutyrosin, ribostamycin
• C12P 21/00 - Preparation of peptides or proteins

Abstract

Provided is a diagnostic assistance device or a diagnostic assistance program that is for identifying a disease with high accuracy without requiring special equipment or the knowledge and skills of a physician. This diagnostic assistance device is for providing assistance in identifying a disease on the basis of image data used for diagnosis, and comprises a calculation unit for calculating color tone-related values with respect to color tones of the image data on the basis of the luminances of the R, G, and B of each pixel forming said image data.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

Abstract

A problem addressed by the present invention is to provide a new screening method for searching for compounds having a browning promoting effect or a browning suppressing effect on brown adipocytes targeting cell membrane receptors (e.g., TRPV1, TRPV 4), based on evaluation of the browning tendency of low-molecular-weight compound-inducible brown adipocytes obtained by direct conversion or induction from somatic cells by a low-molecular-weight compound without performing gene introduction.　An example of the present invention is a screening method for searching for compounds having a browning promoting effect or a browning suppressing effect on brown adipocytes, targeting cell membrane receptors, wherein the screening method includes a step for measuring the browning index of the cells when a candidate compound is and is not made to act on low-molecular-weight compound-inducible brown adipocytes.　According to the present invention, candidate compounds capable of acting on brown adipocytes via TRPV1 or TRPV4 can be discovered.

IPC Classes  ?

• C12Q 1/06 - Quantitative determination
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 15/12 - Genes encoding animal proteins

Abstract

The present invention is primarily directed to provide a new composition for a medium which can be used for differentiation induction from somatic cells to brown adipocytes. The present invention is primarily directed to provide a new composition for a medium which can be used for differentiation induction from somatic cells to brown adipocytes. The present invention can include, for example, a composition for a medium used in differentiation induction from somatic cells to brown adipocytes, wherein the composition comprises the following seven components: a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic. The present invention is primarily directed to provide a new composition for a medium which can be used for differentiation induction from somatic cells to brown adipocytes. The present invention can include, for example, a composition for a medium used in differentiation induction from somatic cells to brown adipocytes, wherein the composition comprises the following seven components: a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic. According to the present invention, direct differentiation induction from somatic cells to brown adipocytes can be effectively performed. In addition, according to the present invention, it is possible to effectively maintain brown adipocytes.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) β signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A01N 1/02 - Preservation of living parts
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• C12N 5/079 - Neural cells
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention is primarily directed to provide a new process capable of performing direct conversion of or induction from a somatic cell to brown adipocytes with low molecular weight compounds, without performing artificial gene transfer. The present invention is primarily directed to provide a new process capable of performing direct conversion of or induction from a somatic cell to brown adipocytes with low molecular weight compounds, without performing artificial gene transfer. The present invention includes, for example, a process for producing brown adipocytes by direct differentiation induction from somatic cells, comprising a step of culturing a somatic cell in a serum-free differentiation induction medium in the presence of a selective PPARγ agonist and a cAMP inducer. The present invention is primarily directed to provide a new process capable of performing direct conversion of or induction from a somatic cell to brown adipocytes with low molecular weight compounds, without performing artificial gene transfer. The present invention includes, for example, a process for producing brown adipocytes by direct differentiation induction from somatic cells, comprising a step of culturing a somatic cell in a serum-free differentiation induction medium in the presence of a selective PPARγ agonist and a cAMP inducer. According to the present invention, direct conversion of or induction from somatic cells to brown adipocytes can be effectively performed without gene transfer. The brown adipocytes obtained by the present invention are useful as regenerative medicine, models of human brown adipocytes and human beige cells, and the like.

IPC Classes  ?

• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

A fluorescence image analyzer has an imaging unit for capturing a first image containing at least a part of a region of a cell as an imaging target for a plurality of cells in a sample in which a target site on a chromosome is labeled with a fluorescent dye, and a second image including fluorescence generated from a fluorescent dye labeling the target site of the cell of the first image. The processing unit selects a plurality of test cells having specific morphological characteristics to be tested from a plurality of cells based on at least the first image, and extracts the bright spots of fluorescence generated from the fluorescent dye. The processing unit identifies cells with chromosomal abnormalities and/or cells without chromosomal abnormalities based on the extracted bright spots, and generates information related to the ratio of cells with chromosomal abnormalities relative to the test cells.

IPC Classes  ?

• C12Q 1/6841 - In situ hybridisation
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The present invention provides a medical image guidance marker to be placed in a body, adapted to be applicable to at least all three types of imaging modalities, namely, MRI, ultrasound, and CT, and to minimize the occurrence of artifacts. The present invention provides a medical image guidance marker to be placed in a body. The medical image guidance marker is made of an alloy with a magnetic susceptibility in the range from −13 ppm to −5 ppm and has a shape of a coil. The coil is formed of a wire with a wire diameter of not less than 0.15 mm and not more than 0.45 mm and has a coil diameter of not less than 0.55 mm and not more than 1.20 mm, and the pitch of the coil is not less than 0.3 mm and not more than 1.5 mm and is not less than 1.8 times and not more than 4 times the wire diameter.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

[Problem] To provide an ophthalmologic device or the like that is capable of non-invasively and objectively classifying dry eye. [Solution] The present invention provides an ophthalmologic device 1 that takes a measurement related to a state of a tear layer on a corneal surface of an eye examination subject and that classifies dry eye by employing the measurement result, the device including: light projecting means 13 for projecting light in a predetermined pattern onto a corneal surface; an image capturing means 14 for repeatedly capturing reflection images of the pattern reflected at the corneal surface; an acquiring means 15 for acquiring, for each of the plurality of captured reflection images, blurriness information in accordance with a value indicating the degree of blurriness in a section in which a luminance value of a reflection image is the highest; a classifying means 17 for acquiring a dry-eye classification result by applying the plurality of acquired time-series blurriness information items to a learning device in which learning therein has been performed by employing a plurality of sets of training input information items, which are a plurality of time-series blurriness information items, and training output information items, which are dry-eye classification results corresponding to said training input information items; and an outputting means 19 for outputting the classification result.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

Abstract

This device for urinary incontinence treatment comprises a sensor for detecting urination, a stimulation pad configured to apply a stimulus to a wearer, and a mechanical part. The mechanical part comprises: a stimulus generating unit that generates a signal causing the stimulation pad to apply a stimulus to a wearer; and a control unit for controlling the stimulus generating unit so as to generate the signal when the sensor detects urination. The stimulation pad comprises a first stimulation pad pair and a second stimulation pad pair. The stimulus generating unit supplies electrical signals with different frequencies ranging from 4,000 to 4,300 Hz to the respective stimulation pad pairs. The differences between the frequencies of the first stimulation pad pair and the frequencies of the second stimulation pad pair are set to fall within the range of 200-300 Hz and the range of 1-10 Hz. The position thereof is arranged such that the electrical signal applied by the first stimulation pad pair and the electrical signal applied by the second stimulation pad pair intersect within the body of the wearer and the interference waves reach the bladder.

IPC Classes  ?

• A41B 9/02 - Drawers or underpants for men, with or without inserted crotch or seat parts
• A41B 9/06 - UndershirtsChemises
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61F 13/42 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators with wetness indicator or alarm
• A61F 5/44 - Devices worn by the patient for reception of urine, faeces, catamenial or other dischargeColostomy devices

Abstract

The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Abstract

Provided are: a vector for treatment of rheumatoid arthritis based on a minus-strand RNA virus, that includes a gene encoding an anti-CD81 antibody; and a pharmaceutical composition for treatment of rheumatoid arthritis that includes the virus vector.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/13 - Immunoglobulins

Abstract

The present disclosure includes a method of producing a cell population containing Chimeric Antigen Receptor (CAR)-expressing immune cells, comprising co-culturing CAR-expressing immune cells and cells expressing a target antigen of the CAR, wherein the CAR-expressing immune cells are cells into which a CAR gene has been introduced and the target antigen-expressing cells are normal blood cells that have been engineered to express the target antigen.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

Provided is a method for producing a three-dimensional tissue body that includes mature adipocytes, said method including a feature of incubating cells that include at least adipose-derived stem cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

An optical microscope for diagnosis according to this embodiment comprises: at least one laser light source (11) that generates a laser light for irradiating a sample (40) containing a light-absorbing substance; a lens that focuses the laser light so as to focus the same on the sample (40); a scanning means that changes the focal position of the laser light with respect to the sample (40); and a light detector (31) that detects, as signal light, the laser light that has passed through the sample (40). As a result of the occurrence of saturation of the absorption by the light-absorbing substance when the laser light intensity is maximized, the intensity of the laser light is changed so as to form a non-linear region where the relationship between the laser light intensity and the signal light intensity is non-linear, and an image, based on the saturation of the absorption by the light-absorbing substance, is generated on the basis of a non-linear component of the signal light.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/483 - Physical analysis of biological material
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G02B 21/00 - Microscopes
• G02B 21/06 - Means for illuminating specimen

Abstract

The purpose of the present invention is to have biodegradable medical implement to dissolve in the living body at a suitable dissolution speed.　This biodegradable medical implement is formed of a magnesium member. In this biodegradable medical equipment, a layer of magnesium crystal grains in which the (0001 face) in a hexagonal structure is aligned towards the obverse surface side is continuous around the entire periphery, in at least one cross-section.

IPC Classes  ?

• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

Disclosed is a cell structure comprising: a fragmented extracellular matrix component; and cells, wherein the cell structure comprises an intercellular vascular network, and the cells comprise at least adipocytes and vascular endothelial cells.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues

Abstract

A purpose of the present invention is to provide a novel assessment method that enables early detection, assessment of severity, and assessment of therapeutic effect, etc., of chronic inflammatory retinal diseases including age-related macular degeneration. Another purpose is to provide a novel therapeutic for inflammatory retinal diseases including age-related macular degeneration and to provide a novel screening method for inflammatory retinal disease therapeutics.　The present invention is a method for assessing inflammatory retinal diseases associated with tissue inflammation, with extracellular vesicles (EV) produced by the retinal pigment epithelial cells (RPE) of a subject being employed as an indicator. This assessment method is characterized in that the profile of miRNA contained in the extracellular vesicles (EV) (especially miR494-3p and/or miR1246) is employed as an indicator.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations

Abstract

Provided is an anti-viral agent, and in particular, an anti-viral agent for coronaviruses such as SARS-CoV-2. This anti-viral agent contains a tea component.

IPC Classes  ?

• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A23L 2/52 - Adding ingredients
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61Q 19/10 - Washing or bathing preparations
• C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins

Abstract

1233 are the same or different and represent a group containing a nitrogen-containing heterocycle; ● represents a carbon atom; and ○ represents a boron atom).

IPC Classes  ?

• C07F 5/02 - Boron compounds
• A61K 33/22 - Boron compounds
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a method for freezing a cell structure, the method comprising freezing a cell structure that contains a fragmented extracellular matrix component, a cell, and fibrin, and that has a three-dimensional organizational structure.

IPC Classes  ?

• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 1/04 - Preserving or maintaining viable microorganisms

Abstract

Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a) ~ (d) given below have been met, and are placed in a suspension state and then preserved. (a) During a period from immediately after a morphology of the human corneal endothelial cells and/or human corneal endothelial precursor cells has shifted from a spindle-shaped to a polygonal shape or an elliptical shape whose major axis-minor axis ratio is close to 1, until immediately before boundaries between the cells become indistinct. (b) During a period from when an expression level of CD44 becomes equal to or less than half a maximum value observed after the most recent subculturing until this expression level reaches a plateau. (c) When the cell density of the human corneal endothelial cells and/or human corneal endothelial precursor cells is not less than 900 cells/mm2 and not more than 2500 cells/mm2. (d) When the number of culturing days since the most recent subculturing is not less than 4 days and not more than 14 days.

IPC Classes  ?

• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention addresses the problem of preserving human corneal endothelial cells and/or human corneal endothelial progenitor cells while maintaining a high survival rate and, in culture after the preservation, minimizing the occurrence ratio of contaminating cells. This preservation method of human corneal endothelial cells and/or human corneal endothelial progenitor cells is characterized by comprising: collecting human corneal endothelial cells and/or human corneal endothelial progenitor cells, said cells having been proliferated using a culture medium which contains a ROCK inhibitor and in which the content of epidermal growth factor (EGF) is lower than the concentration causing transformation, at a time when one or more of the following requirements (a) to (d) are satisfied; and preserving the cells in a suspended state.　(a) The period of time from immediately after a morphological change in the human corneal endothelial cells and/or human corneal endothelial progenitor cells from a spindle shape to a polygonal shape with a long diameter/short diameter ratio close to 1 or a circular shape until immediately before the time when boundaries between the cells become indistinct.　(b) The period from the time when the expression level of CD44 is half or less of the maximum value observed after the latest subculture until the time when the CD44 expression level reaches a plateau.　(c) The time when the cell density of the human corneal endothelial cells and/or human corneal endothelial progenitor cells is from 900 cells/mm2to 2500 cells/mm2 inclusive.　(d) Between 4-14 culture days inclusive after the latest subculture.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 1/04 - Preserving or maintaining viable microorganisms

Abstract

The problem addressed by the present invention is to monitor a subject's circadian rhythm and visualize and present the quality of the subject's circadian rhythm from that data group.　The solution for said problem is an analysis device for analyzing the quality of a subject's circadian rhythm, said analysis device comprising a control unit, wherein the control unit: acquires a measurement data group obtained by monitoring, over time, a signal strength of at least one circadian rhythm–related indicator of the subject; with respect to the acquired measurement data group, carries out, for each indicator, periodic regression analysis using 24 hours as one period; and produces information relating to the quality of the subject's circadian rhythm on the basis of a result of the period regression analysis.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

Disclosed is a peptide which is a partial peptide of cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP), which comprises the amino acid sequence of the conserved region of CAP, and which has at least one of the following effects, i.e., plant stem cell-inducing effect, plant environmental stress tolerance-improving effect, plant pest resistance-inducing effect, germination promoting effect, plant transformation efficiency-enhancing effect and plant growth promoting effect. Also disclosed are a plant stem cell-inducing agent, an environmental stress improving agent, a plant pest resistance-inducing agent, a germination promoting agent, a transformation efficiency-enhancing agent and a plant growth promoting agent, each agent comprising the aforesaid peptide.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A01H 3/00 - Processes for modifying phenotypes
• A01N 63/50 - Isolated enzymesIsolated proteins
• A01P 21/00 - Plant growth regulators
• C12N 5/04 - Plant cells or tissues
• C12N 15/12 - Genes encoding animal proteins

Abstract

Disclosed are a partial peptide of cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP), consisting of an amino acid sequence of the conserved region of CAP, the peptide having at least one effect selected from the following effects: a plant stem cell-inducing effect, a plant environmental stress tolerance-enhancing effect, a plant pest resistance-inducing effect, a germination-promoting effect, a plant transformation efficiency-enhancing effect, and a plant growth-promoting effect; and a plant stem cell inducer, an environmental stress enhancer, a plant pest resistance inducer, a germination promoter, a transformation efficiency enhancer, and a plant growth promoter, all of which comprise the peptide.

IPC Classes  ?

• A01H 3/00 - Processes for modifying phenotypes
• A01N 63/50 - Isolated enzymesIsolated proteins
• A01P 21/00 - Plant growth regulators
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/04 - Plant cells or tissues
• C12N 15/12 - Genes encoding animal proteins

Abstract

An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/06 - Tripeptides
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

An image processing using a plurality of specimen images obtained by successively applying a plurality of types of staining to a specimen to be evaluated and imaging the specimen after staining for at least two types of staining is performed. The image processing comprises: extracting an inner region corresponding to inward of a cell membrane of a single cell in the specimen based on at least one of the specimen images, specifying a cell region corresponding to an individual cell included in the specimen by expanding the inner region outwardly, and performing image cytometry for the cell region based on the specimen images. In analyzing a pathological specimen on a cell-by-cell basis, it is possible to deal with multiple immunostaining and specify the positions of individual cells and evaluate each cell separately even when a cell density in the specimen is high.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06K 9/20 - Image acquisition
• G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
• G06T 7/187 - SegmentationEdge detection involving region growingSegmentationEdge detection involving region mergingSegmentationEdge detection involving connected component labelling
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry

Abstract

To provide a mutant ACE2 protein having higher bindability to an S protein of a coronavirus. A mutant ACE2 protein including an amino acid sequence A represented by SEQ ID NO: 1 or an amino acid sequence C obtained by mutating an amino acid sequence B having 70% or greater identity with the amino acid sequence A, the amino acid sequence C including a substitution ax of at least two amino acids selected from the group consisting of T20, A25, K26, K31, H34, E35, Q60, N64, S70, T78, L79, N90, T92, and Q101 in the amino acid sequence A or a substitution ay corresponding to the substitution ax in the amino acid sequence B.

IPC Classes  ?

• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 19/00 - Hybrid peptides
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

A method of producing a wood-based material that is modified is provided. Specifically, there is provided a method of producing a wood-based material, comprising 1) a step of impregnating a wood-based material with a furan derivative resinification solution that comprises a furan derivative, an inorganic salt inhibiting polymerization of the furan derivative at normal temperature, and an inorganic salt accelerating polymerization of the furan derivative; and 2) a step of polymerizing the furan derivative in the furan derivative resinification solution impregnated into the wood-based material within the wood-based material by means of heating.

IPC Classes  ?

• B27K 3/52 - Impregnating agents containing mixtures of inorganic and organic compounds

Abstract

Provided is a method for producing a modified wood-based material. Specifically, provided is a method for producing a wood-based material, the method including: 1) a step for causing permeation, into a wood-based material, of a furan derivative resinification solution containing a furan derivative, an inorganic salt that suppresses polymerization of the furan derivative at an ordinary temperature, and an inorganic salt that accelerates polymerization of the furan derivative; and 2) a step for, through heating, polymerizing the furan derivative of the permeated furan derivative resinification solution in the wood-based material.

IPC Classes  ?

• B27K 3/52 - Impregnating agents containing mixtures of inorganic and organic compounds

Abstract

It is a main object of the present invention to provide a new producing method capable of efficiently performing direct conversion or induction from a somatic cell to an insulin-producing cell. The present invention can include, for example, a process for producing an insulin-producing cell by direct differentiation induction from a somatic cell, comprising a step of culturing a somatic cell in a serum-free differentiation induction medium, or a step of culturing a somatic cell in a differentiation induction medium containing 5 μg/mL or more of insulin. According to the present invention, insulin-producing cells having a high insulin secretion ability can be produced directly and efficiently from a somatic cell. The insulin-producing cells obtained according to the present invention are useful in regenerative medicine and the like.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

This method of monitoring anesthetic depth includes: acquiring, in time series, an electroencephalographic signal of a first frequency band and an electroencephalographic signal of a second frequency band different from the first frequency band, the signals being derived from a patient under general anesthesia; generating a two-dimensional Poincaré plot with regard to each of the electroencephalographic signal of the first frequency band and the electroencephalographic signal of the second frequency band that have been acquired; acquiring a first value indicative of variation of the plot in a first axial direction and a second value indicative of variation of the plot in a second axial direction orthogonal to the first axis, with respect to each of the Poincaré plots, for respective predetermined durations; (A) acquiring the surface area of the Poincaré plot of the first frequency band from the first value and the second value calculated from the Poincaré plot of the first frequency band, and pi, and (B) acquiring the surface area of the Poincaré plot of the second frequency band from the first value and the second value calculated from the Poincaré plot of the second frequency band, and pi; and providing a value indicative of the anesthetic depth that has been acquired on the basis of the surface area of the Poincaré plot of the first frequency band and the surface area of the Poincaré plot of the second frequency band.

IPC Classes  ?

• A61M 16/01 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes specially adapted for anaesthetising
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses

Abstract

A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

It is a main object of the present invention to provide a process for producing an insulin-producing cell from a somatic cell without performing artificial gene transfer, an insulin-producing cell obtained from the process, or a composition comprising a combination of chemical substances that can be used for the process. The present invention can include, for example: a process for producing an insulin-producing cell from a somatic cell by direct differentiation induction, comprising a step of culturing a somatic cell in the presence of an RSK inhibitor; an insulin-producing cell obtained from the process; and a composition for producing an insulin-producing cell from a somatic cell by directly inducing differentiation, comprising an RSK inhibitor. The insulin-producing cells obtained according to the present invention are useful in regenerative medicine and the like.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The present invention addresses the problem of providing an anti-coronavirus agent, particularly an anti-coronavirus agent against SARS-CoV-2. The problem is solved by an anti-coronavirus agent containing at least one selected from the group consisting of tea extracts, catechin compounds, and theaflavin compounds.

IPC Classes  ?

• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
• A01N 65/08 - Magnoliopsida [dicotyledons]
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A23F 3/16 - Tea extractionTea extractsTreating tea extractMaking instant tea
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61Q 19/10 - Washing or bathing preparations

Abstract

Provided is a new eye disease onset risk evaluation method with which it is possible to evaluate the risk of eye disease onset even in a pre-disease stage. Also provided is a new method with which it is possible to evaluate the progress of a late-stage eye disease.　One example of this invention is an eye disease onset risk or late-stage eye disease progress evaluation method for evaluating an eye disease through molecular dynamics analysis of the anterior chamber environment, the method including a step for using mass spectrometry (MS) to measure the concentration level of metabolites in collected anterior aqueous humor.

IPC Classes  ?

• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides a composition including citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate of citric acid, a hydrate of the pharmaceutically acceptable salt of citric acid, or a mixture thereof. Administration or ingestion of the previous period composition inhibits renal fibrosis in diabetic nephropathy.

IPC Classes  ?

• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

To provide a protein molecule that is useful for an anti-Pseudomonas aeruginosa vaccine. A protein molecule including a PcrV antigen domain and at least one domain selected from the group consisting of OprF antigen domains and Exotoxin A antigen domains.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 39/104 - Pseudomonas
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C07K 19/00 - Hybrid peptides
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins

Abstract

The present invention addresses the problem of providing an antiviral agent, particularly an anti-coronavirus agent for a coronavirus such as SARS-CoV-2. The problem is solved by an antiviral agent comprising at least one selected from the group consisting of (A-components) resveratrol, resveratrol derivatives, resveratrol multimers, derivatives of resveratrol multimers, or sirtuin activators, (B-components) extracts of a plant of the genus Orychophragmus, (C-components) barrigenol or glycosides thereof, (D-components) apigenin or glycosides thereof, (E-components) extracts of a plant of the genus Bellis, (F-components) extracts of a plant of the genus Ilex, (G-components) ulsoric acid or glycosides thereof, (H-components) coumaric acid or glycosides thereof, (I-components) 2-phenylethanol or glycosides thereof, (J-components) tamarixetin or glycosides thereof, and (K-components) sarmentol or glycosides thereof.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/14 - Antivirals for RNA viruses
• A61Q 19/10 - Washing or bathing preparations
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/287 - Chrysanthemum, e.g. daisy
• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A61K 8/34 - Alcohols
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/05 - Phenols
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages

Abstract

[Technical Problem] To provide a novel composition for more efficiently improving endurance than the conventional art. [Solution to Problem] A composition for improving endurance, comprising γ-aminobutyric acid.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A23L 33/17 - Amino acids, peptides or proteins
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention provides cell trait assay techniques which identify cultured human corneal endothelial cells that, in a clinical trial, have been confirmed to express early-stage clinical effects and provide clinical effects that are stable in the long term. Provided is a method for producing functional human corneal endothelial cells which can bring about human corneal function when injected into the anterior chamber of a human eye, said method including a step for growing and/or differentiating/maturing corneal endothelium precursor cells under culturing conditions that can minimize culturing stress such as growth stress. Also provided are functional human corneal endothelial cells which have been found to express a functional protein leading to corneal endothelium (cell) functional characteristics that improve corneal clouding and hydration swelling, and, as a result, sustainably maintain corneal endothelium tissue cell density in the long term and lead to eyesight improvement, or in which proteins that inhibit such corneal endothelium (cell) functional characteristics are have not been elicited or are reduced.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention provides cell trait assay techniques which identify cultured human corneal endothelial cells that, in a clinical trial, have been confirmed to express early-stage clinical effects and provide clinical effects that are stable in the long term. Provided is a method for producing functional human corneal endothelial cells which can bring about human corneal function when injected into the anterior chamber of a human eye, said method including a step for growing and/or differentiating/maturing corneal endothelium precursor cells under culturing conditions that can minimize culturing stress such as growth stress. Also provided are functional human corneal endothelial cells which have been found to express a functional protein leading to corneal endothelium (cell) functional characteristics that improve corneal clouding and hydration swelling, and, as a result, sustainably maintain corneal endothelium tissue cell density in the long term and lead to eyesight improvement, or in which proteins that inhibit such corneal endothelium (cell) functional characteristics are have not been elicited or are reduced.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

Provided are a diagnostic imaging assistance device, a diagnostic imaging assistance system and a diagnostic imaging assistance method with which it is possible to determine a state of a captured image of an anterior eye part by machine learning. A diagnostic imaging assistance system 10 comprises an image processing determination device 12 having: an image database 30 for storing a learning image PL of an anterior eye part and information relating to a state of the learning image PL; and a determination unit 36 for determining the state of a captured subject image P by carrying out machine learning on the basis of the image database 30. This configuration makes it possible to determine the state of the subject image P, which is a captured image of the anterior eye part of the subject, by machine learning.

IPC Classes  ?

• A61B 3/13 - Ophthalmic microscopes

Abstract

It is a main object of the present invention to provide a process for producing a neuron-like cell from a somatic cell, a neuron-like cell obtained thereby, and a composition comprising a combination of chemical substances that can be used for said process without performing artificial gene transfer. It is a main object of the present invention to provide a process for producing a neuron-like cell from a somatic cell, a neuron-like cell obtained thereby, and a composition comprising a combination of chemical substances that can be used for said process without performing artificial gene transfer. The invention can include, for example, a process for producing neuron-like cells, characterized by comprising a step of culturing somatic cells in the presence of two kinds of inhibitors, i.e., a TGF-β inhibitor and a BMP inhibitor, as well as any three or more selected from the group consisting of four kinds, i.e., a cAMP inducer, a GSK3 inhibitor, an Erk-inhibitor, and a p53-inhibitor, wherein the TGF-β inhibitor is a selective ALK5 inhibitor, and a neuron-like cell obtained by said process. It is a main object of the present invention to provide a process for producing a neuron-like cell from a somatic cell, a neuron-like cell obtained thereby, and a composition comprising a combination of chemical substances that can be used for said process without performing artificial gene transfer. The invention can include, for example, a process for producing neuron-like cells, characterized by comprising a step of culturing somatic cells in the presence of two kinds of inhibitors, i.e., a TGF-β inhibitor and a BMP inhibitor, as well as any three or more selected from the group consisting of four kinds, i.e., a cAMP inducer, a GSK3 inhibitor, an Erk-inhibitor, and a p53-inhibitor, wherein the TGF-β inhibitor is a selective ALK5 inhibitor, and a neuron-like cell obtained by said process. The neuron-like cells obtained according to the present invention are useful in regenerative medicine and the like.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

This invention provides a means capable of treating skin ulcers. More specifically, the invention provides a composition for preventing and/or treating skin wounds, the composition comprising carbon monoxide.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present invention addresses the problem of providing a novel composition which is for a medium and can be used to induce differentiation from somatic cells into brown adipocytes.　For example, the present invention may be a composition which is for a differentiation-inducing medium and is used to induce differentiation from somatic cells into brown adipocytes, the composition being characterized by containing seven components: a thyroid hormone receptor agonist; a glucocorticoid receptor agonist; a phosphodiesterase inhibitor; insulin; an ascorbic acid derivative; albumin; and an antibiotic.　According to the present invention, the differentiation of somatic cells into brown adipocytes can be effectively induced. Moreover, according to the present invention, the brown adipocytes can be effectively maintained.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells